Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Blood-based circular RNAs emerge as a breakthrough early diagnostic tool for Alzheimer's disease

22 August 2026 · By · Wire by Fusion42

Published

22 August 2026

Topic

opportunities

◆ Sectors

Health

◆ Geography

China

◆ Source

Read at the-innovation.org →

◆ Verified

Fusion42 · 22 August 2026 · Fusion42 review

Researchers have identified blood-based circular RNAs as a breakthrough biomarker for the early diagnosis of Alzheimer's disease, potentially enabling earlier intervention and improved patient management.

This Wire brief sits within Fusion42's coverage of Health, and 1 source has reported it.

◆ ◆ The Wire takeaway

You now have a new approach to detect Alzheimer's earlier through blood tests, which shifts diagnostic attention from traditional imaging to simpler lab markers. Healthtech founders focused on neurodegenerative disease should explore partnerships to integrate circular RNA testing into clinical workflows.

◆ Coverage

1 source · 22 Aug 2026

◆ Related on Wire

◆ Topics

Healthalzheimersdiagnosticsblood-biomarkerscircular-rnahealthtech